Functions and Targets of miR-335 in Cancer

References

• Lee YS, Dutta A. MicroRNAs in cancer. Annu Rev Pathol. 2009;4:199–227. doi:10.1146/annurev.pathol.4.110807.092222
   PubMed Web of Science ®Google Scholar
• Doench JG, Sharp PA. Specificity of microRNA target selection in translational repression. Genes Dev. 2004;18:504–511. doi:10.1101/gad.1184404
   PubMed Web of Science ®Google Scholar
• Seitz H. Issues in current microRNA target identification methods. RNA Biol. 2017;14:831–834. doi:10.1080/15476286.2017.1320469
   PubMed Web of Science ®Google Scholar
• Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 2007;133:647–658. doi:10.1053/j.gastro.2007.05.022
   PubMed Web of Science ®Google Scholar
• Garofalo M, Quintavalle C, Romano G, Croce CM, Condorelli G. miR221/222 in cancer: their role in tumor progression and response to therapy. Curr Mol Med. 2012;12:27–33. doi:10.2174/156652412798376170
   PubMed Web of Science ®Google Scholar
• Guttilla IK, White BA. Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells. J Biol Chem. 2009;284:23204–23216. doi:10.1074/jbc.M109.031427
   PubMed Web of Science ®Google Scholar
• Tang W, Zhu J, Su S, et al. MiR-27 as a prognostic marker for breast cancer progression and patient survival. PLoS One. 2012;7:e51702. doi:10.1371/journal.pone.0051702
   PubMed Web of Science ®Google Scholar
• Jin C, Wang A, Liu L, Wang G, Li G, Han Z. miR-145-5p inhibits tumor occurrence and metastasis through the NF-κB signaling pathway by targeting TLR4 in malignant melanoma. J Cell Biochem. 2019;120(7):11115–11126. doi:10.1002/jcb.28388
   PubMed Web of Science ®Google Scholar
• Mizuno R, Kawada K, Sakai Y. The molecular basis and therapeutic potential of Let-7 MicroRNAs against colorectal cancer. Can J Gastroenterol Hepatol. 2018;2018:5769591. doi:10.1155/2018/5769591
   PubMed Web of Science ®Google Scholar
• Gulei D, Magdo L, Jurj A, et al. The silent healer: miR-205-5p up-regulation inhibits epithelial to mesenchymal transition in colon cancer cells by indirectly up-regulating E-cadherin expression. Cell Death Dis. 2018;9:66. doi:10.1038/s41419-017-0102-8
   PubMed Web of Science ®Google Scholar
• Bueno MJ, Malumbres M. MicroRNAs and the cell cycle. Biochim Biophys Acta. 2011;1812:592–601. doi:10.1016/j.bbadis.2011.02.002
   PubMed Web of Science ®Google Scholar
• Croce CM, Calin GA. miRNAs, cancer, and stem cell division. Cell. 2005;122:6–7. doi:10.1016/j.cell.2005.06.036
   PubMed Web of Science ®Google Scholar
• Hydbring P, Wang Y, Fassl A, et al. Cell-cycle-targeting MicroRNAs as therapeutic tools against refractory cancers. Cancer Cell. 2017;31:576–590.e578. doi:10.1016/j.ccell.2017.03.004
   PubMed Web of Science ®Google Scholar
• Su Z, Yang Z, Xu Y, Chen Y, Yu Q. MicroRNAs in apoptosis, autophagy and necroptosis. Oncotarget. 2015;6:8474–8490. doi:10.18632/oncotarget.3523
   PubMedGoogle Scholar
• Jovanovic M, Hengartner MO. miRNAs and apoptosis: rNAs to die for. Oncogene. 2006;25:6176–6187. doi:10.1038/sj.onc.1209912
   PubMed Web of Science ®Google Scholar
• Ma L. MicroRNA and metastasis. Adv Cancer Res. 2016;132:165–207.
   PubMed Web of Science ®Google Scholar
• Lou W, Liu J, Gao Y, et al. MicroRNAs in cancer metastasis and angiogenesis. Oncotarget. 2017;8:115787–115802. doi:10.18632/oncotarget.23115
   PubMedGoogle Scholar
• Heyn H, Engelmann M, Schreek S, et al. MicroRNA miR-335 is crucial for the BRCA1 regulatory cascade in breast cancer development. Int J Cancer. 2011;129:2797–2806. doi:10.1002/ijc.25962
   PubMed Web of Science ®Google Scholar
• Wang H, Li M, Zhang R, et al. Effect of miR-335 upregulation on the apoptosis and invasion of lung cancer cell A549 and H1299. Tumour Biol. 2013;34:3101–3109. doi:10.1007/s13277-013-0878-9
   PubMedGoogle Scholar
• Lu Y, Yang H, Yuan L, et al. Overexpression of miR-335 confers cell proliferation and tumour growth to colorectal carcinoma cells. Mol Cell Biochem. 2016;412:235–245. doi:10.1007/s11010-015-2630-9
   PubMed Web of Science ®Google Scholar
• Cao J, Cai J, Huang D, et al. miR-335 represents an invasion suppressor gene in ovarian cancer by targeting Bcl-w. Oncol Rep. 2013;30:701–706. doi:10.3892/or.2013.2482
   PubMed Web of Science ®Google Scholar
• Du W, Tang H, Lei Z, et al. miR-335-5p inhibits TGF-β1-induced epithelial-mesenchymal transition in non-small cell lung cancer via ROCK1. Respir Res. 2019;20:225. doi:10.1186/s12931-019-1184-x
   PubMed Web of Science ®Google Scholar
• Zhang BJ, Gong HY, Zheng F, Liu DJ, Liu HX. Up-regulation of miR-335 predicts a favorable prognosis in esophageal squamous cell carcinoma. Int J Clin Exp Pathol. 2014;7:6213–6218.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Shen P. miR-335 acts as a tumor suppressor and enhances ionizing radiation-induced tumor regression by targeting ROCK1. Front Oncol. 2020;10:278. doi:10.3389/fonc.2020.00278
   PubMed Web of Science ®Google Scholar
• Liu J, Bian T, Feng J, et al. miR-335 inhibited cell proliferation of lung cancer cells by target Tra2β. Cancer Sci. 2018;109:289–296. doi:10.1111/cas.13452
   PubMedGoogle Scholar
• Yang B, Huang J, Liu H, Guo W, Li G. miR-335 directly, while miR-34a indirectly modulate survivin expression and regulate growth, apoptosis, and invasion of gastric cancer cells. Tumour Biol. 2016;37:1771–1779. doi:10.1007/s13277-015-3951-8
   PubMedGoogle Scholar
• Wang Y, Zhao W, Fu Q. miR-335 suppresses migration and invasion by targeting ROCK1 in osteosarcoma cells. Mol Cell Biochem. 2013;384:105–111. doi:10.1007/s11010-013-1786-4
   PubMed Web of Science ®Google Scholar
• Kim Y, Kim H, Park D, Jeoung D. miR-335 targets SIAH2 and confers sensitivity to anti-cancer drugs by increasing the expression of HDAC3. Mol Cells. 2015;38:562–572. doi:10.14348/molcells.2015.0051
   PubMed Web of Science ®Google Scholar
• Zhao W, Chen T, Zhao Y. Upregulated lncRNA CASC9 contributes to progression of non-small cell lung cancer through inhibition of miR-335-3p and activation S100A14 expression. Onco Targets Ther. 2020;13:6027–6036. doi:10.2147/OTT.S249973
   PubMed Web of Science ®Google Scholar
• Tang H, Du W, Jiang Y, Li H, Bo H, Song S. Upregulated expression of ROCK1 promotes cell proliferation by functioning as a target of miR-335-5p in non-small cell lung cancer. J Cell Physiol. 2019. doi:10.1002/jcp.28886
   Web of Science ®Google Scholar
• Tang H, Zhu J, Du W, et al. CPNE1 is a target of miR-335-5p and plays an important role in the pathogenesis of non-small cell lung cancer. J Exp Clin Cancer Res. 2018;37:131. doi:10.1186/s13046-018-0811-6
   PubMed Web of Science ®Google Scholar
• Ramadan A, Hashim M, Swellam M. Expression of MiR-335 and its target metalloproteinase genes: clinical significance in breast cancer. Arch Physiol Biochem. 2020;1–7. doi:10.1080/13813455.2019.1703004
   Web of Science ®Google Scholar
• Hao J, Lai M, Liu C. Expression of miR-335 in triple-negative breast cancer and its effect on chemosensitivity. J buon. 2019;24:1526–1531.
   PubMed Web of Science ®Google Scholar
• Chen JH, Huang WC, Bamodu OA, Chang PM, Chao TY, Huang TH. Monospecific antibody targeting of CDH11 inhibits epithelial-to-mesenchymal transition and represses cancer stem cell-like phenotype by up-regulating miR-335 in metastatic breast cancer, in vitro and in vivo. BMC Cancer. 2019;19:634. doi:10.1186/s12885-019-5811-1
   PubMed Web of Science ®Google Scholar
• Jia Q, Ye L, Xu S, et al. Circular RNA 0007255 regulates the progression of breast cancer through miR-335-5p/SIX2 axis. Thorac Cancer. 2020;11:619–630. doi:10.1111/1759-7714.13306
   PubMed Web of Science ®Google Scholar
• Xie Y, Deng H, Wei R, et al. Overexpression of miR-335 inhibits the migration and invasion of osteosarcoma by targeting SNIP1. Int J Biol Macromol. 2019;133:137–147. doi:10.1016/j.ijbiomac.2019.04.016
   PubMed Web of Science ®Google Scholar
• Liu ZF, Liang ZQ, Li L, et al. MiR-335 functions as a tumor suppressor and regulates survivin expression in osteosarcoma. Eur Rev Med Pharmacol Sci. 2016;20:1251–1257.
   PubMed Web of Science ®Google Scholar
• Zare A, Ahadi A, Larki P, et al. The clinical significance of miR-335, miR-124, miR-218 and miR-484 downregulation in gastric cancer. Mol Biol Rep. 2018;45:1587–1595. doi:10.1007/s11033-018-4278-5
   PubMed Web of Science ®Google Scholar
• Liu H, Li W, Chen C, Pei Y, Long X. MiR-335 acts as a potential tumor suppressor miRNA via downregulating ROCK1 expression in hepatocellular carcinoma. Tumour Biol. 2015;36:6313–6319. doi:10.1007/s13277-015-3317-2
   PubMedGoogle Scholar
• Gao L, Yang Y, Xu H, et al. MiR-335 functions as a tumor suppressor in pancreatic cancer by targeting OCT4. Tumour Biol. 2014;35:8309–8318. doi:10.1007/s13277-014-2092-9
   PubMedGoogle Scholar
• Li H, Xie S, Liu M, et al. The clinical significance of downregulation of mir-124-3p, mir-146a-5p, mir-155-5p and mir-335-5p in gastric cancer tumorigenesis. Int J Oncol. 2014;45:197–208. doi:10.3892/ijo.2014.2415
   PubMed Web of Science ®Google Scholar
• Zhang LL, Zhang LF, Guo XH, Zhang DZ, Yang F, Fan YY. Downregulation of miR-335-5p by long noncoding RNA ZEB1-AS1 in gastric cancer promotes tumor proliferation and invasion. DNA Cell Biol. 2018;37:46–52. doi:10.1089/dna.2017.3926
   PubMed Web of Science ®Google Scholar
• Zhang D, Yang N. MiR-335-5p inhibits cell proliferation, migration and invasion in colorectal cancer through downregulating LDHB. J buon. 2019;24:1128–1136.
   PubMed Web of Science ®Google Scholar
• Wang K, Chen X, Zhan Y, et al. miR-335 inhibits the proliferation and invasion of clear cell renal cell carcinoma cells through direct suppression of BCL-W. Tumour Biol. 2015;36:6875–6882. doi:10.1007/s13277-015-3382-6
   PubMedGoogle Scholar
• Cao J, Cai J, Huang D, et al. miR-335 represents an independent prognostic marker in epithelial ovarian cancer. Am J Clin Pathol. 2014;141:437–442. doi:10.1309/AJCPLYTZGB54ISZC
   PubMed Web of Science ®Google Scholar
• Liu XK, Chen D, Li X. MiR-335 suppresses cell proliferation and migration by upregulating CRKL in bladder cancer. Eur Rev Med Pharmacol Sci. 2019;23:2399–2408. doi:10.26355/eurrev_201903_17386
   PubMed Web of Science ®Google Scholar
• Zhang P, Yang X, Wang L, Zhang D, Luo Q, Wang B. Overexpressing miR335 inhibits DU145 cell proliferation by targeting early growth response 3 in prostate cancer. Int J Oncol. 2019;54:1981–1994. doi:10.3892/ijo.2019.4778
   PubMed Web of Science ®Google Scholar
• Yang Y, Wang F, Huang H, Zhang Y, Xie H, Men T. lncRNA SLCO4A1-AS1 promotes growth and invasion of bladder cancer through sponging miR-335-5p to upregulate OCT4. Onco Targets Ther. 2019;12:1351–1358. doi:10.2147/OTT.S191740
   PubMedGoogle Scholar
• Liu R, Guo H, Lu S. MiR-335-5p restores cisplatin sensitivity in ovarian cancer cells through targeting BCL2L2. Cancer Med. 2018;7:4598–4609. doi:10.1002/cam4.1682
   PubMed Web of Science ®Google Scholar
• Luo L, Xia L, Zha B, et al. miR-335-5p targeting ICAM-1 inhibits invasion and metastasis of thyroid cancer cells. Biomed Pharmacother. 2018;106:983–990. doi:10.1016/j.biopha.2018.07.046
   PubMed Web of Science ®Google Scholar
• Wang W, Chen LC, Qian JY, Zhang Q. MiR-335 promotes cell proliferation by inhibiting MEF2D and sensitizes cells to 5-Fu treatment in gallbladder carcinoma. Eur Rev Med Pharmacol Sci. 2019;23:9829–9839. doi:10.26355/eurrev_201911_19546
   PubMed Web of Science ®Google Scholar
• Dou XQ, Chen XJ, Zhou Q, Wen MX, Zhang SZ, Zhang SQ. miR-335 modulates Numb alternative splicing via targeting RBM10 in endometrial cancer. Kaohsiung J Med Sci. 2020;36:171–177. doi:10.1002/kjm2.12149
   PubMed Web of Science ®Google Scholar
• Yan Z, Xiong Y, Xu W, et al. Identification of hsa-miR-335 as a prognostic signature in gastric cancer. PLoS One. 2012;7:e40037. doi:10.1371/journal.pone.0040037
   PubMed Web of Science ®Google Scholar
• Wang L, Zhao Y, Xu M, Zhou F, Yan J. Serum miR-1301-3p, miR-335-5p, miR-28-5p, and their target B7-H3 may serve as novel biomarkers for colorectal cancer. J buon. 2019;24:1120–1127.
   PubMed Web of Science ®Google Scholar
• Cui L, Hu Y, Bai B, Zhang S. Serum miR-335 level is associated with the treatment response to trans-arterial chemoembolization and prognosis in patients with hepatocellular carcinoma. Cell Physiol Biochem. 2015;37:276–283. doi:10.1159/000430352
   PubMedGoogle Scholar
• Liang H, Zhang C, Guan H, Liu J, Cui Y. LncRNA DANCR promotes cervical cancer progression by upregulating ROCK1 via sponging miR-335-5p. J Cell Physiol. 2019;234:7266–7278. doi:10.1002/jcp.27484
   PubMed Web of Science ®Google Scholar
• Li HW, Liu J. Circ_0009910 promotes proliferation and metastasis of hepatocellular carcinoma cells through miR-335-5p/ROCK1 axis. Eur Rev Med Pharmacol Sci. 2020;24:1725–1735. doi:10.26355/eurrev_202002_20349
   PubMedGoogle Scholar
• Wang H, Zhang M, Sun G. Long non-coding RNA NEAT1 regulates the proliferation, migration and invasion of gastric cancer cells via targeting miR-335-5p/ROCK1 axis. Pharmazie. 2018;73:150–155. doi:10.1691/ph.2018.7877
   PubMed Web of Science ®Google Scholar
• Wang Y, Zeng X, Wang N, et al. Long noncoding RNA DANCR, working as a competitive endogenous RNA, promotes ROCK1-mediated proliferation and metastasis via decoying of miR-335-5p and miR-1972 in osteosarcoma. Mol Cancer. 2018;17:89. doi:10.1186/s12943-018-0837-6
   PubMed Web of Science ®Google Scholar
• Wang K, Jin W, Song Y, Fei X. LncRNA RP11-436H11.5, functioning as a competitive endogenous RNA, upregulates BCL-W expression by sponging miR-335-5p and promotes proliferation and invasion in renal cell carcinoma. Mol Cancer. 2017;16:166. doi:10.1186/s12943-017-0735-3
   PubMed Web of Science ®Google Scholar
• Thirunavukarasou A, Singh P, Govindarajalu G, Bandi V, Baluchamy S. E3 ubiquitin ligase Cullin4B mediated polyubiquitination of p53 for its degradation. Mol Cell Biochem. 2014;390:93–100. doi:10.1007/s11010-014-1960-3
   PubMed Web of Science ®Google Scholar
• Yu C, Ying J, Yu K, Shen W, Jiang M. Circ_0074027 contributes to nonsmall cell lung cancer progression by upregulating CUL4B expression through miR-335-5p. Cancer Biother Radiopharm. 2020. doi:10.1089/cbr.2020.3579
   Web of Science ®Google Scholar
• Takeo K, Kawai T, Nishida K, et al. Oxidative stress-induced alternative splicing of transformer 2beta (SFRS10) and CD44 pre-mRNAs in gastric epithelial cells. Am J Physiol Cell Physiol. 2009;297:C330–338. doi:10.1152/ajpcell.00009.2009
   PubMed Web of Science ®Google Scholar
• Liu J, Yao L, Zhang M, Jiang J, Yang M, Wang Y. Downregulation of LncRNA-XIST inhibited development of non-small cell lung cancer by activating miR-335/SOD2/ROS signal pathway mediated pyroptotic cell death. Aging (Albany NY). 2019;11:7830–7846. doi:10.18632/aging.102291
   PubMedGoogle Scholar
• Li Q, Wang XJ, Jin JH. SOX2-induced upregulation of lncRNA LINC01510 promotes papillary thyroid carcinoma progression by modulating miR-335/SHH and activating Hedgehog pathway. Biochem Biophys Res Commun. 2019;520:277–283. doi:10.1016/j.bbrc.2019.09.138
   PubMed Web of Science ®Google Scholar
• Sah NK, Khan Z, Khan GJ, Bisen PS. Structural, functional and therapeutic biology of survivin. Cancer Lett. 2006;244:164–171. doi:10.1016/j.canlet.2006.03.007
   PubMed Web of Science ®Google Scholar
• Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer. 2008;8:61–70. doi:10.1038/nrc2293
   PubMed Web of Science ®Google Scholar
• An Y, Cai H, Zhang Y, et al. circZMYM2 competed endogenously with miR-335-5p to regulate JMJD2C in pancreatic cancer. Cell Physiol Biochem. 2018;51:2224–2236. doi:10.1159/000495868
   PubMedGoogle Scholar
• Atlasi Y, Mowla SJ, Ziaee SA, Gokhale PJ, Andrews PW. OCT4 spliced variants are differentially expressed in human pluripotent and nonpluripotent cells. Stem Cells. 2008;26:3068–3074. doi:10.1634/stemcells.2008-0530
   PubMed Web of Science ®Google Scholar
• Zhu Y, Jiang X, Zhang S, Wang L, Zhou Q, Jiang J. Hsa_circ_103973 acts as a sponge of miR-335 to promote cervical cancer progression. Onco Targets Ther. 2020;13:1777–1786. doi:10.2147/OTT.S215736
   PubMed Web of Science ®Google Scholar
• Wang Y, Yang T, Zhang Z, et al. Long non-coding RNA TUG1 promotes migration and invasion by acting as a ceRNA of miR-335-5p in osteosarcoma cells. Cancer Sci. 2017;108:859–867. doi:10.1111/cas.13201
   PubMed Web of Science ®Google Scholar
• Wang Q, Hu X, Du M, et al. ZNRD1-AS1 promotes nasopharyngeal carcinoma cell invasion and metastasis by regulating the miR-335-ROCK1 Axis. Onco Targets Ther. 2020;13:4779–4790. doi:10.2147/OTT.S250028
   PubMed Web of Science ®Google Scholar
• Gong M, Ma J, Guillemette R, et al. miR-335 inhibits small cell lung cancer bone metastases via IGF-IR and RANKL pathways. Mol Cancer Res. 2014;12:101–110. doi:10.1158/1541-7786.MCR-13-0136
   PubMed Web of Science ®Google Scholar
• Gao Y, Zeng F, Wu JY, et al. MiR-335 inhibits migration of breast cancer cells through targeting oncoprotein c-Met. Tumour Biol. 2015;36:2875–2883. doi:10.1007/s13277-014-2917-6
   PubMedGoogle Scholar
• Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9:153–166. doi:10.1038/nrc2602
   PubMed Web of Science ®Google Scholar
• Krasinska L, Domingo-Sananes MR, Kapuy O, et al. Protein phosphatase 2A controls the order and dynamics of cell-cycle transitions. Mol Cell. 2011;44:437–450. doi:10.1016/j.molcel.2011.10.007
   PubMed Web of Science ®Google Scholar
• Tang R, Lei Y, Hu B, et al. WW domain binding protein 5 induces multidrug resistance of small cell lung cancer under the regulation of miR-335 through the Hippo pathway. Br J Cancer. 2016;115:243–251. doi:10.1038/bjc.2016.186
   PubMed Web of Science ®Google Scholar
• Guo X, Yu L, Zhang Z, Dai G, Gao T, Guo W. miR-335 negatively regulates osteosarcoma stem cell-like properties by targeting POU5F1. Cancer Cell Int. 2017;17:29. doi:10.1186/s12935-017-0398-6
   PubMed Web of Science ®Google Scholar
• Pascal JM. The comings and goings of PARP-1 in response to DNA damage. DNA Repair (Amst). 2018;71:177–182. doi:10.1016/j.dnarep.2018.08.022
   PubMed Web of Science ®Google Scholar
• Luo Y, Tong L, Meng H, et al. MiR-335 regulates the chemo-radioresistance of small cell lung cancer cells by targeting PARP-1. Gene. 2017;600:9–15. doi:10.1016/j.gene.2016.11.031
   PubMed Web of Science ®Google Scholar
• Yan L, Liu G, Cao H, Zhang H, Shao F. Hsa_circ_0035483 sponges hsa-miR-335 to promote the gemcitabine-resistance of human renal cancer cells by autophagy regulation. Biochem Biophys Res Commun. 2019;519:172–178. doi:10.1016/j.bbrc.2019.08.093
   PubMed Web of Science ®Google Scholar
• Chen S, Xia X. Long noncoding RNA NEAT1 suppresses sorafenib sensitivity of hepatocellular carcinoma cells via regulating miR-335-c-Met. J Cell Physiol. 2019.
   Web of Science ®Google Scholar
• McKinsey TA, Zhang CL, Olson EN. MEF2: a calcium-dependent regulator of cell division, differentiation and death. Trends Biochem Sci. 2002;27:40–47. doi:10.1016/S0968-0004(01)02031-X
   PubMed Web of Science ®Google Scholar
• Tan HY, Wang N, Lam W, Guo W, Feng Y, Cheng YC. Targeting tumour microenvironment by tyrosine kinase inhibitor. Mol Cancer. 2018;17:43. doi:10.1186/s12943-018-0800-6
   PubMed Web of Science ®Google Scholar
• Turley SJ, Cremasco V, Astarita JL. Immunological hallmarks of stromal cells in the tumour microenvironment. Nat Rev Immunol. 2015;15:669–682. doi:10.1038/nri3902
   PubMed Web of Science ®Google Scholar
• Mao Y, Keller ET, Garfield DH, Shen K, Wang J. Stromal cells in tumor microenvironment and breast cancer. Cancer Metastasis Rev. 2013;32:303–315. doi:10.1007/s10555-012-9415-3
   PubMed Web of Science ®Google Scholar
• Gascard P, Tlsty TD. Carcinoma-associated fibroblasts: orchestrating the composition of malignancy. Genes Dev. 2016;30:1002–1019. doi:10.1101/gad.279737.116
   PubMed Web of Science ®Google Scholar
• Orimo A, Gupta PB, Sgroi DC, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005;121:335–348. doi:10.1016/j.cell.2005.02.034
   PubMed Web of Science ®Google Scholar
• Swartz MA, Iida N, Roberts EW, et al. Tumor microenvironment complexity: emerging roles in cancer therapy. Cancer Res. 2012;72:2473–2480. doi:10.1158/0008-5472.CAN-12-0122
   PubMed Web of Science ®Google Scholar
• Wang F, Li L, Piontek K, Sakaguchi M, Selaru FM. Exosome miR-335 as a novel therapeutic strategy in hepatocellular carcinoma. Hepatology. 2018;67:940–954. doi:10.1002/hep.29586
   PubMed Web of Science ®Google Scholar
• Kabir TD, Leigh RJ, Tasena H, et al. A miR-335/COX-2/PTEN axis regulates the secretory phenotype of senescent cancer-associated fibroblasts. Aging (Albany NY). 2016;8:1608–1635. doi:10.18632/aging.100987
   PubMedGoogle Scholar
• Viallard C, Larrivée B. Tumor angiogenesis and vascular normalization: alternative therapeutic targets. Angiogenesis. 2017;20:409–426. doi:10.1007/s10456-017-9562-9
   PubMed Web of Science ®Google Scholar
• Taniguchi K, Karin M. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Semin Immunol. 2014;26:54–74.
   PubMed Web of Science ®Google Scholar
• Li S, Miao T, Sebastian M, et al. The transcription factors Egr2 and Egr3 are essential for the control of inflammation and antigen-induced proliferation of B and T cells. Immunity. 2012;37:685–696. doi:10.1016/j.immuni.2012.08.001
   PubMed Web of Science ®Google Scholar
• Liu D, Evans I, Britton G, Zachary I. The zinc-finger transcription factor, early growth response 3, mediates VEGF-induced angiogenesis. Oncogene. 2008;27:2989–2998. doi:10.1038/sj.onc.1210959
   PubMed Web of Science ®Google Scholar
• Steg AD, Katre AA, Bevis KS, et al. Smoothened antagonists reverse taxane resistance in ovarian cancer. Mol Cancer Ther. 2012;11:1587–1597. doi:10.1158/1535-7163.MCT-11-1058
   PubMed Web of Science ®Google Scholar
• Murone M, Rosenthal A, de Sauvage FJ. Hedgehog signal transduction: from flies to vertebrates. Exp Cell Res. 1999;253:25–33. doi:10.1006/excr.1999.4676
   PubMed Web of Science ®Google Scholar
• Nybakken K, Perrimon N. Hedgehog signal transduction: recent findings. Curr Opin Genet Dev. 2002;12:503–511. doi:10.1016/S0959-437X(02)00333-7
   PubMed Web of Science ®Google Scholar
• Pasca Di Magliano M, Hebrok M. Hedgehog signalling in cancer formation and maintenance. Nat Rev Cancer. 2003;3:903–911. doi:10.1038/nrc1229
   PubMed Web of Science ®Google Scholar
• Li Y, Zhang D, Chen C, Ruan Z, Li Y, Huang Y. MicroRNA-212 displays tumor-promoting properties in non-small cell lung cancer cells and targets the hedgehog pathway receptor PTCH1. Mol Biol Cell. 2012;23:1423–1434. doi:10.1091/mbc.e11-09-0777
   PubMed Web of Science ®Google Scholar
• Rimkus TK, Carpenter RL, Qasem S, Chan M, Lo HW. Targeting the Sonic Hedgehog signaling pathway: review of smoothened and GLI inhibitors. Cancers (Basel). 2016;8(2):22. doi:10.3390/cancers8020022
   PubMed Web of Science ®Google Scholar
• Dienstmann R, Rodon J, Serra V, Tabernero J. Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors. Mol Cancer Ther. 2014;13:1021–1031. doi:10.1158/1535-7163.MCT-13-0639
   PubMed Web of Science ®Google Scholar
• Jung SN, Kang YE, Lee GH, et al. Brn3a/Pou4f1 functions as a tumor suppressor by targeting c-MET/STAT3 signaling in thyroid cancer. J Clin Endocrinol Metab. 2020;105(9):e3127–e3141. doi:10.1210/clinem/dgaa316
   Web of Science ®Google Scholar
• Sanchez-Vega F, Mina M, Armenia J, et al. Oncogenic signaling pathways in the cancer genome atlas. Cell. 2018;173:321–337.e310.
   PubMed Web of Science ®Google Scholar
• Liu H, Du S, Lei T, et al. Multifaceted regulation and functions of YAP/TAZ in tumors (Review). Oncol Rep. 2018;40:16–28. doi:10.3892/or.2018.6423
   PubMed Web of Science ®Google Scholar
• Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell. 2011;146:353–358. doi:10.1016/j.cell.2011.07.014
   PubMed Web of Science ®Google Scholar
• Zhao L, Han T, Li Y, et al. The lncRNA SNHG5/miR-32 axis regulates gastric cancer cell proliferation and migration by targeting KLF4. FASEB j. 2017;31:893–903. doi:10.1096/fj.201600994R
   PubMed Web of Science ®Google Scholar
• Zhong Y, Du Y, Yang X, et al. Circular RNAs function as ceRNAs to regulate and control human cancer progression. Mol Cancer. 2018;17:79. doi:10.1186/s12943-018-0827-8
   PubMed Web of Science ®Google Scholar
• Chen D, Chen T, Guo Y, Wang C, Dong L, Lu C. Platycodin D (PD) regulates LncRNA-XIST/miR-335 axis to slow down bladder cancer progression in vitro and in vivo. Exp Cell Res. 2020;396:112281. doi:10.1016/j.yexcr.2020.112281
   PubMed Web of Science ®Google Scholar
• Li H, Zhu H, Zhou Y, et al. Long non-coding RNA MSTO2P promotes the proliferation and colony formation in gastric cancer by indirectly regulating miR-335 expression. Tumour Biol. 2017;39:1010428317705506.
   Google Scholar
• Xie F, Zhang L, Yao Q, et al. TUG1 promoted tumor progression by sponging miR-335-5p and regulating CXCR4-mediated infiltration of pro-tumor immunocytes in CTNNB1-mutated hepatoblastoma. Onco Targets Ther. 2020;13:3105–3115. doi:10.2147/OTT.S234819
   PubMed Web of Science ®Google Scholar
• Li R, Wang Y, Xu Y, He X, Li Y. Silencing the long noncoding RNA, TINCR, a molecular sponge of miR335, inhibits the malignant phenotype of epithelial ovarian cancer via FGF2 suppression. Int J Oncol. 2019;55:1110–1124. doi:10.3892/ijo.2019.4875
   PubMed Web of Science ®Google Scholar
• Wang Q, Wang T, Hu Y, et al. Circ-EIF4G3 promotes the development of gastric cancer by sponging miR-335. Pathol Res Pract. 2019;215:152507. doi:10.1016/j.prp.2019.152507
   PubMed Web of Science ®Google Scholar
• Wang S, Li Y, Sun S, Cai J, Cao J. Sp1 promotes ovarian cancer cell migration through repressing miR-335 expression. Biochem Biophys Res Commun. 2020;524:211–216. doi:10.1016/j.bbrc.2020.01.063
   PubMed Web of Science ®Google Scholar
• Dohi O, Yasui K, Gen Y, et al. Epigenetic silencing of miR-335 and its host gene MEST in hepatocellular carcinoma. Int J Oncol. 2013;42:411–418. doi:10.3892/ijo.2012.1724
   PubMed Web of Science ®Google Scholar
• Slabakova E, Culig Z, Remsik J, Soucek K. Alternative mechanisms of miR-34a regulation in cancer. Cell Death Dis. 2017;8:e3100. doi:10.1038/cddis.2017.495
   PubMed Web of Science ®Google Scholar
• van Zandwijk N, Pavlakis N, Kao SC, et al. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, Phase 1, open-label, dose-escalation study. Lancet Oncol. 2017;18:1386–1396. doi:10.1016/S1470-2045(17)30621-6
   PubMed Web of Science ®Google Scholar